Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $1.97B |
| Gross Profit (TTM) | $-341.55M |
| EBITDA | $-17.53M |
| Operating Margin | 13.00% |
| Return on Equity | -9.48% |
| Return on Assets | -1.13% |
| Revenue/Share (TTM) | $19.00 |
| Book Value | $14.46 |
| Price-to-Book | 1.25 |
| Price-to-Sales (TTM) | 0.97 |
| EV/Revenue | 1.099 |
| EV/EBITDA | 16.91 |
| Quarterly Earnings Growth (YoY) | 2664.00% |
| Quarterly Revenue Growth (YoY) | -34.30% |
| Shares Outstanding | $105.63M |
| Float | $94.66M |
| % Insiders | 4.93% |
| % Institutions | 103.42% |
Volatility is currently contracting
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
Sarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing cash and investments by approximately $197 million during the quarter to $945 million.
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. “As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead,” said Michael Severino, MD, chief executive officer, Sarepta Therapeutics. “Our second quarter results, including $328.7 m.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Dr. Se.
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta's Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transiti.
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentati.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SRPT and any ticker you trade — then tracks every position and per-strategy win rate.
